Search results for "Lipids"

showing 10 items of 2228 documents

Lipoprotein abnormalities in chronic kidney disease and renal transplantation

2021

Chronic kidney disease (CKD) is one of the most important risk factors for cardiovascular disease (CVD). Despite the kidney having no direct implications for lipoproteins metabolism, advanced CKD dyslipidemia is usually present in patients with CKD, and the frequent lipid and lipoprotein alterations occurring in these patients play a role of primary importance in the development of CVD. Although hypertriglyceridemia is the main disorder, a number of lipoprotein abnormalities occur in these patients. Different enzymes pathways and proteins involved in lipoprotein metabolism are impaired in CKD. In addition, treatment of uremia may modify the expression of lipoprotein pattern as well as deter…

medicine.medical_specialtyLipoproteins030232 urology & nephrologyDiseaseReview030204 cardiovascular system & hematologyurologic and male genital diseasesGastroenterologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineInternal medicineChronic kidney diseasemedicinelcsh:ScienceEcology Evolution Behavior and SystematicsKidneybusiness.industryHypertriglyceridemiaPaleontologymedicine.diseaseCardiovascular diseaseLipidsUremiafemale genital diseases and pregnancy complicationsTransplantationmedicine.anatomical_structureSpace and Planetary Sciencelipids (amino acids peptides and proteins)lcsh:QbusinessDyslipidemiaKidney diseaseLipoprotein
researchProduct

Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents

2014

Abstract Adipose tissue is an endocrine organ that secretes a number of hormones and metabolically active substances that impact energy metabolism and insulin sensitivity. These inflammatory markers are collectively referred to as adipocytokines, or adipokines. Adipose tissue's functional capacity and metabolic activity vary among individuals, thus partly explaining the incomplete overlap between obesity and the metabolic syndrome. The functional failure of adipose tissues results in changed energy delivery and impaired glucose consumption, triggering self-regulatory mechanisms to maintain homeostasis. Antihyperglycemic, hypolipidemic, antiobesity, and angiotensin II receptor blocker drugs …

medicine.medical_specialtyLipoproteinsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdipokineAdipose tissueIncretinsNiacinAnti-Obesity AgentsInsulin resistanceAdipokinesInternal medicineInternal MedicineAnimalsHumansHypoglycemic AgentsInsulinMedicineHypolipidemic AgentsMetabolic Syndromebusiness.industryInsulinFibric AcidsEzetimibemedicine.diseaseLipidsMetforminGlucoseEndocrinologyAdipose TissueHypolipidemic AgentsAzetidinesThiazolidinedionesAnti-Obesity AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsInsulin ResistanceMetabolic syndromebusinessHormoneMetabolic Syndrome and Related Disorders
researchProduct

Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.

2004

Type 2 diabetes is an important cardiovascular risk factor. A significant component of the risk associated with type 2 diabetes is thought to be because of its characteristic lipid "triad" profile of raised small dense low-density lipoprotein levels, lowered high-density lipoprotein, and elevated triglycerides (TGs). Trials of statins and fibrates have included substantial numbers of patients with diabetes and indicate that lipid lowering reduces cardiovascular event rates in these patients. However, statins alone do not always address all the lipid abnormalities of diabetes. Fibrates, which have low affinity for peroxisome proliferator-activated receptor alpha (PPARalpha), improve most asp…

medicine.medical_specialtyLipoproteinsPeroxisome proliferator-activated receptorType 2 diabetesInsulin resistanceRisk FactorsInternal medicineDiabetes mellitusmedicineLipolysisHumansPPAR alphaDyslipidemiaschemistry.chemical_classificationbusiness.industrynutritional and metabolic diseasesLipid metabolismmedicine.diseaseLipid MetabolismEndocrinologychemistryDiabetes Mellitus Type 2Cardiovascular Diseaseslipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaLipoproteinAmerican heart journal
researchProduct

El papel de la dislipemia aterogénica en las guías de práctica clínica.

2016

Background and objective Atherogenic dyslipidaemia is underdiagnosed, undertreated, and under-controlled. The aim of the present study was to assess the positioning of clinical guidelines as regards atherogenic dyslipidaemia. Material and method The major clinical guidelines of scientific societies or official agencies issued between January 1, 2012 and March 31, 2015 were collected from the MEDLINE database. High-density lipoprotein (HDL) cholesterol, triglycerides, atherogenic dyslipidaemia, non-HDL cholesterol, and apolipoprotein (apo) B were gathered from the 10 selected guidelines, and it was assessed whether these parameters were considered a cardiovascular risk factor, a therapeutic …

medicine.medical_specialtyLow HDL-cholesterolendocrine system diseasesApolipoprotein BNice030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCardiovascular preventionInternal medicinemental disordersmedicinePharmacology (medical)cardiovascular diseases030212 general & internal medicineRisk factorcomputer.programming_languagebiologybusiness.industryCholesterolnutritional and metabolic diseasesClinical Practicechemistrybiology.proteinlipids (amino acids peptides and proteins)Atherogenic dyslipidaemia Cardiovascular prevention Cholesterol Colesterol Dislipemia aterogénica Guías de práctica clínica Lipids Lípidos Practice guidelines Prevención cardiovascular Triglicéridos TriglyceridesCardiology and Cardiovascular MedicinebusinesscomputerLipoprotein
researchProduct

Low-density lipoprotein size and cardiovascular risk assessment

2017

A predominance of small, dense low-density lipoproteins (LDL) has been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. LDL size seems to be an important predictor of cardiovascular events and progression of coronary heart disease and evidences suggests that both quality (particularly small, dense LDL) and quantity may increase cardiovascular risk. However, other authors have suggested that LDL size measurement does not add information beyond that obtained by measuring LDL concentration, triglyceride levels and HDL concentrations. Therefore, it remains debatable whether to measure LDL particle size in cardiovascular …

medicine.medical_specialtyLow-density lipoprotein cardiovascular risk610 Medicine & health2700 General MedicineRisk Assessment142-005 142-005chemistry.chemical_compoundClofibric AcidRisk FactorsInternal medicinemedicineHumansClinical significanceRisk factorParticle SizeNational Cholesterol Education ProgramHypolipidemic AgentsTriglyceridebusiness.industryVascular diseaseAnticholesteremic AgentsConfoundingGeneral Medicinemedicine.diseaseLipoproteins LDLEndocrinologychemistryCardiovascular DiseasesLow-density lipoproteinCardiologylipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessRisk assessment
researchProduct

0347: Beneficial cardiovascular effects of O-GlcNAc stimulation in early phase of septic shock

2016

BackgroundO-GlcNAcylation, a post-translational modification, is the end product of the hexosamine biosynthetic pathway (HBP). Recent studies showed beneficial effects of its increase in acute pathologies, such as hemorrhagic shock. We postulated that increase in total protein OGlcNAcylation at the early phase of septic shock, a systemic inflammation associated with a cardiovascular dysfunction, could improve cardiovascular function and reduce mortality.MethodsTo induce an endotoxemic shock, rats (n=6-8) received iv either lipopolysaccharide (LPS, 5mg/kg) or saline (CTRL). After 1 h, fluid resuscitation (FR,15mL/kg of colloid, iv) was associated or not with HBP substrate: glucosamine (GlcN,…

medicine.medical_specialtyMean arterial pressureResuscitationTroponin TLipopolysaccharideSeptic shockbusiness.industryStimulationPharmacologymedicine.diseaseSystemic inflammationSurgerychemistry.chemical_compoundchemistryShock (circulatory)medicinelipids (amino acids peptides and proteins)medicine.symptomCardiology and Cardiovascular MedicinebusinessArchives of Cardiovascular Diseases Supplements
researchProduct

Postprandial metabolism: from research to clinical practice.

2013

Over the last decade, the importance of postprandial metabolism has increased, given that it is the physiological state of humans in modern society. Moreover, postprandial lipemia is considered as a key player in the development of the most important cardiometabolic diseases. In this regard, postprandial lipemia has become more important, since it has been demonstrated that nonfasting triglycerides (TGs) are independent predictors of the risk of cardio vascular disease (CVD) [1,2]. Interestingly, the postprandial phase has been associated with increased inflammation and oxidation, which influences vascular function through a permanent endothelial aggression by atherogenic lipoprotein. TGs a…

medicine.medical_specialtyMediterranean dietbusiness.industryEndocrinology Diabetes and Metabolismdigestive oral and skin physiologycardiovascular disease lipoproteins Mediterranean diet metabolic syndrome postprandial lipemia triglyceridesInflammationMetabolismmedicine.diseaseClinical PracticeEndocrinologyPostprandialInternal medicinemedicinelipids (amino acids peptides and proteins)Metabolic syndromemedicine.symptomRisk factorCardiology and Cardiovascular MedicinebusinessChylomicron
researchProduct

A review of recent evidence in human studies of n-3 and n-6 PUFA intake on cardiovascular disease, cancer, and depressive disorders: does the ratio r…

2015

AbstractPolyunsaturated fatty acids (PUFAs) have been considered of great interest for human health due to their potential anti-inflammatory action that may protect from a number of chronic-degenerative diseases with an inflammatory pathogenesis. This review aimed to report the most updated evidence of both n-3 and n-6 PUFAs effect on cardiovascular disease, cancer, and depression in humans. Attention has been also paid to those studies exploring the effects of the ratio intake. Results from pooled analyses of human studies reported a general positive effect of n-3 PUFAs intake on all outcomes considered. In contrast, the role of n-6 PUFAs on human health needs to be better assessed in orde…

medicine.medical_specialtyN 6 pufachronic diseases inflammation polyunsaturated fatty acidsDiseaseBiologyBioinformaticsHuman healthInternal medicineFatty Acids Omega-6NeoplasmsFatty Acids Omega-3medicineHumansSettore MED/49 - Scienze Tecniche Dietetiche ApplicateDepression (differential diagnoses)chemistry.chemical_classificationDepressive DisorderHuman studiesfood and beveragesCancermedicine.diseaseEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Food AnalysisFood SciencePolyunsaturated fatty acidInternational journal of food sciences and nutrition
researchProduct

Ezetimibe/Simvastatin 10/20 mg Versus Rosuvastatin 10 mg in High Risk Hypercholesterolemic Patients Stratified by Previous Statin Treatment Potency

2010

Objective: This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva) versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization. Methods: Patients with elevated low-density lipoprotein cholesterol (LDL-C) despite prior statin treatment (n = 618) were randomized 1:1 to EZ/Simva 10/20 mg or Rosuva 10 mg for 6 weeks. Percent change from baseline in lipids and attainment of lipid targets were assessed within each subgroup (low potency n = 369, high potency n = 249). Consistency of the treatment effect across subgroups was evaluated by testing for treatment-by-subgroup interaction. No multiplicity adjustm…

medicine.medical_specialtyNutrition and DieteticsStatinRandomizationApolipoprotein Bbiologymedicine.drug_classbusiness.industryEndocrinology Diabetes and MetabolismUrologyPharmacologyEzetimibeSimvastatinInternal Medicinemedicinebiology.proteinPotencylipids (amino acids peptides and proteins)Ezetimibe/simvastatinRosuvastatinCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Clinical Lipidology
researchProduct

Nutraceuticals as Lipid-Lowering Treatment in Pregnancy and Their Effects on the Metabolic Syndrome.

2015

Maternal nutrition and lifestyle before and during pregnancy influence both mother and offspring's health and can be correlated with the metabolic syndrome in later life. Findings from animal and human studies indicate that nutrition during pregnancy has an important role in microbiological, metabolic, physiologic and immunologic development and homeostasis. A low nutritional intake in early pregnancy may represent a risk for adverse effects during pregnancy as well as on birth outcome. It seems that dietary supplementation with probiotics in perinatal period may represent safe and practical approach in dealing with the most common adverse pregnancy outcomes such as obesity and gestational …

medicine.medical_specialtyOffspringPharmaceutical SciencePhysiologyOverweight03 medical and health sciences0302 clinical medicinePregnancyDiabetes mellitusInternal medicinemedicineAnimalsHumans030212 general & internal medicineObesityAdverse effectMetabolic SyndromePregnancybusiness.industryProbioticsmedicine.diseaseObesityLipidsGestational diabetesDiabetes GestationalEndocrinologyTreatment OutcomeDietary SupplementsFemaleMetabolic syndromemedicine.symptombusiness030217 neurology & neurosurgeryBiotechnologyCurrent pharmaceutical biotechnology
researchProduct